How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies

In the last five years, everolimus has demonstrated efficacy in the treatment of neuroendocrine tumors (NETs) of different origins; its efficacy and safety were explored in the RADIANT trials, the last of which (RADIANT-4) has been recently published (December 2015). Overall, evidence collected from...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Pusceddu, Sara, De Braud, Filippo, Russo, Giuseppe Lo, Concas, Laura, Femia, Daniela, Vernieri, Claudio, Indini, Alice, Formisano, Barbara, Buzzoni, Roberto
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2016
Assuntos:
Review
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5190138/
https://ncbi.nlm.nih.gov/pubmed/27057638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8601
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares